Since Bcl-3 expression could be linked to unfavorable prognosis of breast cancer patients that received endocrine treatment, Bcl-3 may be a suitable biomarker for predicting endocrine therapy response of patients with ERα-/PR-positive breast cancers. The gene discussed is BCL3; the disease is breast cancer.